Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Emergent BioSolutions
< Previous
1
2
Next >
Emergent BioSolutions Reports First Quarter 2025 Financial Results
May 07, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
May 01, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
April 22, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces Stock Repurchase Program
March 31, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
March 20, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
March 20, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
HKMPY
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
March 19, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
March 18, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
March 13, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
March 12, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
March 10, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
March 03, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
February 18, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
February 07, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
January 16, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
January 14, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
January 13, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
January 08, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
January 08, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
December 16, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
November 06, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
November 06, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
November 04, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
October 23, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
October 08, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
October 02, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
September 26, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
September 13, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
September 25, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
September 12, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.